Duos Technologies Group (NASDAQ:DUOT) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a strategic shift toward data centers, including plans to divest its legacy rail business and expand newer data center infrastructure and sourcing operations. Strategic shi
Duos Technologies Group (NASDAQ:DUOT) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a strategic shift toward data centers, including plans to divest its legacy rail business and expand newer data center infrastructure and sourcing operations. Strategic shi
CALGARY, Alberta, March 31, 2026 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its financial and operating results for the fourth quarter and year ended December 31, 2025, along with its year-end reserves. Prairie Provident's audited annual consolidated financial statements and related Management's Discussion and Analysis ("MD&A") f...
CALGARY, Alberta, March 31, 2026 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its financial and operating results for the fourth quarter and year ended December 31, 2025, along with its year-end reserves. Prairie Provident's audited annual consolidated financial statements and related Management's Discussion and Analysis ("MD&A") for the year ended December 31, 2025, and Annual Information Form dated March 31, 2026 containing year-end reserves data and other information for the period, are available on the Company's website at www.ppr.ca and filed on SEDAR+ at www.sedarplus.ca .
Last-day gains didn’t stop the S&P 500 from tallying its worst first quarter since 2022 as the Iran conflict, private-credit worries and the AI ‘scare trade’ weighed on stocks in March.
Last-day gains didn’t stop the S&P 500 from tallying its worst first quarter since 2022 as the Iran conflict, private-credit worries and the AI ‘scare trade’ weighed on stocks in March.
TEHRAN, IRAN - MARCH 02: A general view of Tehran with smoke visible in the distance after explosions were reported in the city, on March 02, 2026 in Tehran, Iran. (Photo by Contributor/Getty Images)
TEHRAN, IRAN - MARCH 02: A general view of Tehran with smoke visible in the distance after explosions were reported in the city, on March 02, 2026 in Tehran, Iran. (Photo by Contributor/Getty Images)
Sector cites ‘billions of pounds in additional costs’ from new business rates and increase in minimum wage thresholds Two-thirds of hospitality businesses are planning to cut jobs as a result of “suffocating” costs imposed by government, as new business rates and higher wage bills come into force. Many pubs, restaurants and hotel companies will see their costs increase significantly from 1 April a...
Sector cites ‘billions of pounds in additional costs’ from new business rates and increase in minimum wage thresholds Two-thirds of hospitality businesses are planning to cut jobs as a result of “suffocating” costs imposed by government, as new business rates and higher wage bills come into force. Many pubs, restaurants and hotel companies will see their costs increase significantly from 1 April after Rachel Reeves’s changes to business rates and an increase in minimum wage thresholds announced at the chancellor’s November budget. Continue reading...
London Coliseum Superbly cast, the dancer brings stratospheric levels of charisma to a rather pedestrian show driven by Cyndi Lauper’s songs Johannes Radebe ( AKA Jojo from Strictly ) is a born performer. He is utterly magnetic on stage, and when he’s dancing you can’t take your eyes off him. The role of the drag queen Lola in Kinky Boots could have been written for Radebe, whose entrances alone a...
London Coliseum Superbly cast, the dancer brings stratospheric levels of charisma to a rather pedestrian show driven by Cyndi Lauper’s songs Johannes Radebe ( AKA Jojo from Strictly ) is a born performer. He is utterly magnetic on stage, and when he’s dancing you can’t take your eyes off him. The role of the drag queen Lola in Kinky Boots could have been written for Radebe, whose entrances alone are a thing to behold – rising from a trapdoor, say, draped in a floor-length crimson gown and wearing a curly blond wig, part Diana Ross, part Whitney Houston. The musical is based on the 2005 film inspired by the real-life story of a troubled Northampton shoe factory that switches to making thigh-high boots for drag queens. It’s a riot of feathers and sparkle, with designers Robert Jones and Tom Rogers going all out on the costumes. The foil to Lola’s otherworldly glamour is the everyman character Charlie Price (usually played by 2010 X Factor winner Matt Cardle, but due to illness, by understudy Liam Doyle on the night I watch). Charlie is likable, directionless, pulled back home from London by the death of his father to reluctantly take over the ailing family business. A chance encounter with Lola and her friends leads to a mad scheme to save the factory, and a bit of culture clash comedy. Kinky Boots approaches gender and sexuality in a warm, good-humoured way, and lightly explores themes of fathers and sons, expectations and acceptance. Continue reading...
UK researcher uses maths to explain seeming inevitability of phenomenon experienced by many motorists It is a situation experienced by many motorists: one driver overtakes another only to find the slower car is right behind them when they reach a red light. Now a researcher has used mathematics to reveal why the situation feels inevitable. Dr Conor Boland from Dublin City University has called his...
UK researcher uses maths to explain seeming inevitability of phenomenon experienced by many motorists It is a situation experienced by many motorists: one driver overtakes another only to find the slower car is right behind them when they reach a red light. Now a researcher has used mathematics to reveal why the situation feels inevitable. Dr Conor Boland from Dublin City University has called his work “The Voorhees law of traffic”. Continue reading...
There is a section of Scotland supporters who have taken to booing the head coach and the team. With a World Cup coming, they need to keep perspective, writes Tom English.
There is a section of Scotland supporters who have taken to booing the head coach and the team. With a World Cup coming, they need to keep perspective, writes Tom English.
Novo Nordisk A/S ’s obesity drug Wegovy will be an option for about 1.2 million more patients in England’s National Health Service, after the drug price regulator recommended it to prevent heart attacks and strokes. The decision will significantly expand access to Wegovy on the state-run NHS, where the blockbuster drug is currently available through specialist weight-management services, limiting ...
Novo Nordisk A/S ’s obesity drug Wegovy will be an option for about 1.2 million more patients in England’s National Health Service, after the drug price regulator recommended it to prevent heart attacks and strokes. The decision will significantly expand access to Wegovy on the state-run NHS, where the blockbuster drug is currently available through specialist weight-management services, limiting its uptake. The National Institute for Health and Care Excellence is now recommending it to treat overweight patients who have had a heart attack or stroke, or have serious circulation problems in their legs. The regulator, which assesses the cost-effectiveness of drugs, has faced intense pressure from the pharmaceutical industry over its stringent criteria. Last year, the UK agreed to a 25% spending boost by lifting the threshold it uses to determine if a drug represents value for money. Under the new recommendations for Wegovy, patients must have a body mass index of 27 or more to access the shot, alongside other criteria linked to risk of heart attacks and strokes. That BMI is lower than the threshold currently used for access to Wegovy — or Eli Lilly & Co. ’s rival drug Mounjaro — for weight loss. The drug will be offered as part of existing cardiovascular care, meaning doctors will be able to consider Wegovy as an option alongside standard treatments, Novo said in a separate statement. The drug regulator estimates that patient population at about 1.2 million. Wegovy’s approval in the UK to protect against heart disease is based on a large study, backed by Novo, that found the drug cut the risk of heart attack and stroke by a fifth. Current NHS restrictions on eligibility for Wegovy for weight loss means most patients access the drug via private prescriptions. Lilly’s Mounjaro is also being rolled out on the NHS via a phased program for weight loss, limiting access.